Dr. Tian Zhang, MD
Claim this profileUniversity of Texas Southwestern Medical Center at Dallas
Studies Renal Cell Carcinoma
Studies Kidney Cancer
11 reported clinical trials
14 drugs studied
Area of expertise
1Renal Cell Carcinoma
Stage IV
Stage III
2Kidney Cancer
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Tian Zhang, MD is currently running
Registry
for Advanced Prostate Cancer
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices. Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of five years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs. PROMs questionnaires will be collected at enrollment and every three months thereafter. Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment. As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment due to progression of disease. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.
Recruiting1 award N/A5 criteria
Cabozantinib + Nivolumab
for Kidney Cancer
This trial is testing higher doses of cabozantinib or a combination of cabozantinib with nivolumab in patients with advanced kidney cancer who did not respond to previous treatment. Cabozantinib stops cancer growth, while nivolumab helps the immune system fight the cancer. Cabozantinib and nivolumab have been used together to treat advanced renal cell carcinoma, showing benefits in disease control and survival.
Recruiting1 award Phase 2
More about Tian Zhang, MD
Clinical Trial Related1 year of experience running clinical trials · Led 11 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Tian Zhang, MD has experience with
- Nivolumab
- Cabozantinib
- Enfortumab Vedotin
- Pembrolizumab
- Standard Of Care
- Lutetium Lu 177 Vipivotide Tetraxetan
Breakdown of trials Tian Zhang, MD has run
Renal Cell Carcinoma
Kidney Cancer
Prostate Cancer
Bladder Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tian Zhang, MD specialize in?
Tian Zhang, MD focuses on Renal Cell Carcinoma and Kidney Cancer. In particular, much of their work with Renal Cell Carcinoma has involved Stage IV patients, or patients who are Stage III.
Is Tian Zhang, MD currently recruiting for clinical trials?
Yes, Tian Zhang, MD is currently recruiting for 5 clinical trials in Dallas Texas. If you're interested in participating, you should apply.
Are there any treatments that Tian Zhang, MD has studied deeply?
Yes, Tian Zhang, MD has studied treatments such as Nivolumab, Cabozantinib, Enfortumab Vedotin.
What is the best way to schedule an appointment with Tian Zhang, MD?
Apply for one of the trials that Tian Zhang, MD is conducting.
What is the office address of Tian Zhang, MD?
The office of Tian Zhang, MD is located at: University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 United States. This is the address for their practice at the University of Texas Southwestern Medical Center at Dallas.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.